Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our Scientific Advisory Board ranks the submitted proposals based on their scientific merit and their alignment with Cure SMA’s research priorities. Funding is then awarded to […]
Cure SMA is excited to share an important update to our travel support programs. In response to community feedback and the growing need for accessible travel support for younger individuals, we have expanded eligibility for our Travel Support Package to now include teens with SMA. Previously available only to adults with SMA, the Travel Support
Cure SMA Expands Travel Support Package Eligibility to Include Teens with SMA Read More »
Today, Genentech announced the discontinuation of emugrobart (an investigational anti-myostatin antibody, also known as GYM329) into Phase III development for spinal muscular atrophy (SMA). The decision to stop clinical development of emugrobart in SMA follows a comprehensive assessment of the totality of the evidence from Part 1 of the MANATEE ( NCT05115110 ) study –
Genentech Issues Community Letter Regarding Emugrobart Read More »
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our Scientific Advisory Board ranks the submitted proposals based on their scientific merit and their alignment with Cure SMA’s research priorities. Funding is then awarded to
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our Scientific Advisory Board ranks the submitted proposals based on their scientific merit and their alignment with Cure SMA’s research priorities. Funding is then awarded to
Cure SMA Awards $150,000 Grant to Christian Simon, PhD, at Leipzig University in Germany Read More »
Novartis recently shared a Winter 2026 update highlighting the FDA approval of ITVISMA® (onasemnogene abeparvovec-brve) for intrathecal use in people ages 2 and older with SMA, offering a one-time gene replacement therapy option. The update also includes ongoing engagement opportunities with the SMA community, upcoming ITVISMA webinars, Adaptive Sports and Recreation resources from Cure SMA,
Novartis Releases Winter SMA Community Update Letter Read More »
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our Scientific Advisory Board ranks the submitted proposals based on their scientific merit and their alignment with Cure SMA’s research priorities. Funding is then awarded to
Cure SMA Awards $75,000 Grant to Jiangbing Zhou, PhD, at Yale University Read More »
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our Scientific Advisory Board ranks the submitted proposals based on their scientific merit and their alignment with Cure SMA’s research priorities. Funding is then awarded to
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our Scientific Advisory Board ranks the submitted proposals based on their scientific merit and their alignment with Cure SMA’s research priorities. Funding is then awarded to
Cure SMA Awards $150,000 Grant to Anton Blatnik, PhD, at Case Western Reserve University Read More »
Today, Biogen announced the publication of results from the pivotal Phase 2/3 DEVOTE study in Nature Medicine, highlighting the potential benefits of a high-dose regimen of nusinersen for people living with spinal muscular atrophy (SMA). The study evaluated a higher loading and maintenance dose regimen of nusinersen and demonstrated improvements across key areas, including motor
Biogen Announces Results from the Phase 2/3 DEVOTE Study Read More »
